Targeting AR, alone or combined with other therapeutic agents, provides alternatives to the existing therapies for BC, for instance enzalutamide and bicalutamide are two AR antagonists, which are in clinical trials to determine their efficacy alone to treat ER+ BC (NCT01889238 and NCT00468715, respectively). Here, ESR1 is linked to breast cancer.